Pharvaris (NASDAQ:PHVS) Insider Anna Nijdam Sells 1,829 Shares

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 1,829 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $30.60, for a total value of $55,967.40. Following the transaction, the insider directly owned 48,945 shares in the company, valued at approximately $1,497,717. This represents a 3.60% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anna Nijdam also recently made the following trade(s):

• On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The shares were sold at an average price of $30.74, for a total value of $169,100.74.

Pharvaris Trading Up 0.7%

Shares of NASDAQ PHVS traded up $0.20 during trading hours on Tuesday, hitting $29.88. 191,721 shares of the company traded hands, compared to its average volume of 227,155. The stock has a market capitalization of $1.95 billion, a price-to-earnings ratio of -9.40 and a beta of -2.34. The company’s 50 day moving average price is $28.52 and its 200 day moving average price is $26.90. Pharvaris N.V. has a 12 month low of $15.46 and a 12 month high of $33.33.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.12. Equities analysts anticipate that Pharvaris N.V. will post -3.25 EPS for the current year.

Hedge Funds Weigh In On Pharvaris

A number of large investors have recently bought and sold shares of PHVS. Tudor Investment Corp ET AL purchased a new stake in shares of Pharvaris in the 3rd quarter worth $1,943,000. Patient Square Capital LP lifted its holdings in shares of Pharvaris by 41.4% in the 3rd quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after buying an additional 101,098 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 710.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock worth $676,000 after buying an additional 23,743 shares during the period. Integral Health Asset Management LLC purchased a new stake in shares of Pharvaris in the 3rd quarter worth $4,990,000. Finally, Boothbay Fund Management LLC lifted its holdings in shares of Pharvaris by 735.1% in the 3rd quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after buying an additional 118,994 shares during the period.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a report on Tuesday, March 3rd. Wolfe Research began coverage on Pharvaris in a report on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Citizens Jmp dropped their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Finally, Wedbush boosted their price objective on Pharvaris from $41.00 to $42.00 and gave the company an “outperform” rating in a report on Tuesday, April 7th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.